Microalbuminuria and urinary albumin excretion in clinical practice Microalbuminuria y excreción urinaria de albúmina en la práctica clínica
Author
dc.contributor.author
Tagle, Rodigo
Author
dc.contributor.author
González, Fernando
Author
dc.contributor.author
Acevedo, Mónica
Admission date
dc.date.accessioned
2019-03-15T16:03:37Z
Available date
dc.date.available
2019-03-15T16:03:37Z
Publication date
dc.date.issued
2012
Cita de ítem
dc.identifier.citation
Revista Medica de Chile, Volumen 140, Issue 6, 2018, Pages 797-805
Identifier
dc.identifier.issn
00349887
Identifier
dc.identifier.issn
07176163
Identifier
dc.identifier.other
10.4067/S0034-98872012000600016
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165870
Abstract
dc.description.abstract
Microalbuminuria is a new tool in the management of patients with diabetes mellitus or hypertension. Microalbuminuria is an easily measured biomarker in a urine sample. Urinary albumin to creatinine ratio in first morning urine sample correlates with 24 hours urinary albumin excretion, but it is easier to obtain, and can identify hypertensive or diabetic patients with high risk for cardiovascular events. Therapeutic interventions such as renin angiotensin system blockade have demonstrated their usefulness in reducing urinary albumin excretion in clinical studies. It would be advisable to incorporate urinary albumin to creatinine ratio to the routine clinical monitoring of patients with cardiovascular risk, such as those with hypertension and diabetes mellitus.